Akero Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKRO research report →
Range $38 – $56
Price Chart
About the company
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being.
- CEO
- Andrew Cheng
- IPO
- 2019
- Employees
- 69
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on AKRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.50B
- P/E
- -29.54
- Fwd P/E
- 68.31
- PEG
- -131.55
- P/S
- 0.00
- P/B
- 4.68
- EV/EBITDA
- -28.86
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -15.33%
- ROIC
- -17.85%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-285,423,000
- Net Income
- $-252,060,000-66.1%
- EPS
- $-3.75-29.8%
- OCF Growth
- -58.3%
- FCF Growth
- -59.0%
- 52W High
- $58.40
- 52W Low
- $21.34
- 50D MA
- $53.06
- 200D MA
- $48.19
- Beta
- -0.40
- RSI (14)
- 69
- Avg Volume
- 2.56M
No earnings-call transcripts are available for AKRO yet.
- Free Float
- 86.4%
- Shares Outstanding
- 82.32M
- Float Shares
- 71.11M
of shares held by institutions
286 13F filers
Buy/sell ratio 0.18. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AKRO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Buy | Nov 8, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nuveen Asset Management, LLC | 171.52K | ▼ 3.38K |
| Axa Investment Managers S.A. | 71.20K | ▲ 71.20K |
| Allostery Investments LP | 22.50K | ▲ 4.50K |
| Springhill Fund Asset Management (Hk) Co Ltd | 19.93K | ▼ 131.28K |
| Nebula Research & Development LLC | 14.79K | ▲ 14.79K |
| Wolverine Trading, LLC | 5.06K | ▲ 5.06K |
| Point72 (Difc) Ltd | 3.69K | ▲ 3.69K |
| Lindbrook Capital, LLC | 1.61K | ▲ 50 |
Held by 16 ETFs
Biggest fund positions in AKRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 9, 25 | Heyman Tomas J. | sell | 13,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 26,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 15,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 15,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 9,398 |
| Dec 9, 25 | Xu Yuan | sell | 9,398 |
| Dec 9, 25 | Xu Yuan | sell | 15,000 |
| Dec 9, 25 | Xu Yuan | sell | 15,000 |
| Dec 9, 25 | Xu Yuan | sell | 13,000 |
| Dec 9, 25 | Xu Yuan | sell | 26,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AKRO coverage
Recent articles, reports, and earnings notes.
No research on AKRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKRO report →Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO
defenseworld.net · Jan 3
Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO
defenseworld.net · Dec 22
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
defenseworld.net · Dec 13
Novo Nordisk has completed its acquisition of Akero Therapeutics
globenewswire.com · Dec 9
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
businesswire.com · Nov 20
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
prnewswire.com · Nov 12
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
globenewswire.com · Nov 7
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
prnewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.